Pitsafe-4
The 7th Statin For More Tolerability


Composition : Pitavastatin 4mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option; Pitavastatin may reduce the risk of heart attack, stroke and even death up to 68 percent of patients. More than 20,000 patients with hypercholesterolemia who were treated with pitavastatin for up to 2 years, the LDL-C (low-density lipoprotein cholesterol) target rate recommended by the Japanese Atherosclerosis Society (JAS) was achieved by 88.2% of low-risk patients (<160 mg/dL), 82.7% of intermediate-risk patients (<140 mg/dL), 66.5% of high-risk patients (<120 mg/dL), and 50.3% of secondary prevention patients (<100 mg/dL). In patients with low HDL-C, a significant reduction of total cholesterol (TC; -21.0%), LDL-C (-31.3%), and triglyceride (TG) (-6.1%) was seen at 104 weeks- Int J Clin Pract. 2005 Feb;59(2):239-52.

View more products with following salts

Pitsafe-2
The 7th Statin For More Tolerability


Composition : Pitavastatin 2mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option; Pitavastatin may reduce the risk of heart attack, stroke and even death up to 68 percent of patients. More than 20,000 patients with hypercholesterolemia who were treated with pitavastatin for up to 2 years, the LDL-C (low-density lipoprotein cholesterol) target rate recommended by the Japanese Atherosclerosis Society (JAS) was achieved by 88.2% of low-risk patients (<160 mg/dL), 82.7% of intermediate-risk patients (<140 mg/dL), 66.5% of high-risk patients (<120 mg/dL), and 50.3% of secondary prevention patients (<100 mg/dL). In patients with low HDL-C, a significant reduction of total cholesterol (TC; -21.0%), LDL-C (-31.3%), and triglyceride (TG) (-6.1%) was seen at 104 weeks- Int J Clin Pract. 2005 Feb;59(2):239-52.

View more products with following salts

Pitsafe-FB
Who can't tolerate the side effects of statins


Composition : Pitavastatin 2mg + Fenofibrate 67.5mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : Co-administration of pitavastatin and fenofibrate should be considered as one of the options for the treatment of hypercholestrolemic patients with hupertriglyceridemia, in whom, control of the lipid profile sometimes becomes problematic in routine clinical practice - Japanese Clincal Medicine 2011:2 57-66 Pitvastatin and atorvastatin cuased significant and almost comparable reductions in serum levels of total cholesterol (-35.4 vs -33.8%), low-density lipoprotein cholesterol (-42.8 vs.-40.7%), and triglyceride (-26.1 vs -29.4%) and significantly increased serum levels of high-density lipoprotein cholesterol (12.1 vs 11.4%). Under these conditions, plasma levels of CoQ10 were reduced by atorvastatin (-26.1%, P=0.0007) but not by pitavastatin (-7.7%, P=0.39) - Clin Pharmacol Ther, 2008 May;83(5):731-9

View more products with following salts

Pitsafe-EZ
The 7th statin for more tolerability


Composition : Pitavastatin 2mg + Ezetimibe 10mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was predictor of poor response to aggressive lipid lowering treatment in ACS patients - journal of Lipids Volume 2015 Study demonstrated for the first time that co-administration of ezetimibe 10mg enhanced proteinuria-lowering effects of pitavastatin 2mg. in non-diabetic CKD patients partly via a cholesterol-independent manner, Ezetimibe may have pleiotropic actions that could contribute to reno-protective properties of this lipid-lowering agent - Clinical Pharmacokinetics, May 2005, Volume 44, Issue 5, pp 467-494

View more products with following salts